Is PLRX or PMCB more undervalued in 2026?

CirclFi compares Pliant Therapeutics, Inc. (PLRX) and PharmaCyte Biotech, Inc. (PMCB) using 13 institutional-grade valuation models. PLRX has a Quality of Company score of 4.3/10 while PMCB scores 5.1/10.

Which is a better buy — PLRX or PMCB?

Compare intrinsic values from 13 independent models against current market prices. CirclFi also calculates Value Trap scores. This is not financial advice — conduct your own analysis.

How do PLRX and PMCB valuations compare?

PLRX at $1.25 and PMCB at $0.86 are compared across Bayesian DCF, EPV, EROIC Spread, First Chicago, Markov DDM, and 8 additional models.

PLRX vs PMCB Valuation Comparison 2026 — Intrinsic Value Analysis

PLRX

Biotechnology

Pliant Therapeutics, Inc.

Quality

4.3

out of 10

Value Trap

LOW

Price

$1.25

Last close

Models

7/13

Active

PMCB

Biotechnology

PharmaCyte Biotech, Inc.

Quality

5.1

out of 10

Value Trap

SAFE

Price

$0.86

Last close

Models

4/13

Active

Model-by-Model Comparison

Model	Type	PLRX Fair Value	PLRX Upside	PMCB Fair Value	PMCB Upside
Bayesian DCF	Intrinsic	$0.12	-90.6%	—	—
EROIC Spread	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
First Chicago	Scenario	$0.63	-48.2%	$5.13	+498.5%
ML-RIV	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
Dynamic NAV	Asset-Based	$3.22	+157.7%	$2.46	+186.9%
PWERM	Option-Based	$•••.••	••.•%	$•••.••	••.•%
Sentiment SOTP	Hybrid	$•••.••	••.•%	$•••.••	••.•%
CUCE Ensemble	Ensemble	$•••.••	••.•%	$•••.••	••.•%

🔒

Unlock Full 13-Model Comparison

Access all valuation models for PLRX vs PMCB — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

PLRX vs PMCB — Which Stock Is More Undervalued?

PMCB scores higher with a 5.1/10 quality rating vs PLRX's 4.3/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Pliant Therapeutics, Inc. (PLRX) and PharmaCyte Biotech, Inc. (PMCB) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

PLRX currently trades at $1.25 with a QOC of 4.3/10, while PMCB trades at $0.86 with a QOC of 5.1/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).